semaglutide and zepbound Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). For educational comparison only—these are Ozempic vs Zepbound for Weight

Pay only for what you order

Canada became the first G7 country to approve a generic semaglutide in April 2026, after Novo Nordisk failed to maintain a key Canadian patent covering acylated GLP-1 compounds

Retatrutide Titration Protocols Retatrutide follows a similar gradual escalation pattern, though the dose increments differ [14]: Typical Retatrutide Escalation: Weeks 1-4: 2 mg weekly Weeks 5-8: 4 mg weekly (first studied therapeutic dose) Weeks 9-12: 6-8 mg weekly (intermediate range) Weeks 13-16: 8-12 mg weekly (maximum studied doses) Week 17+: Maintenance at target dose The longer titration period (16 weeks to reach maximum dose) helps mitigate the significant gastrointestinal effects associated with retatrutide's multi-receptor activation

Always inspect the packaging and cold packs upon receipt to verify proper temperature maintenance during transit

The subcutaneous formulations are administered once weekly, with steady-state concentrations achieved after approximately 4 to 5 weeks of consistent dosing

Potassium food additives and dietary management of serum potassium: proposed best-practice recommendations